Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Recruiting N/A Interventional Study
Alzheimer Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
90 (estimated)
Sponsor
Centre Hospitalier St Anne · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study aims to analyse, in vivo, the interplay between microglial activation and tau pathology in Alzheimer's disease (AD) using \[18F\]-DPA-714 and \[18F\]-Ro948 tracers by Position Emission Tomography (PET), and their consequences on synaptic density using \[11C\]-UCB-J, a recent PET radioligand. By coupling advanced neuroimaging techniques in AD patients, while comparing them to controls, …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: General Inclusion Criteria: * Adult (older than 18 years) * Women old enough to procreate under effective contraception * Signed consent * Absence of general or systemic disorders that may interfere with cognition. Inclusion criteria for EOAD and LOAD patients: * Progressive …
Contacts

Khaoussou SYLLA, MD, PhD

01.45.65.76.78

k.sylla@ghu-paris.fr

CONTACT

Viviane Awassi

v.awassi@ghu-paris.fr

CONTACT